Sort   by:  
 Page size 
ProteomicsIdentification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. F...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000084343 | MassIVE
ProteomicsIdentification of tumor antigens in the HLA peptidome of patient-derived xenograft tumors in mouse
Personalized cancer immunotherapy targeting patient-specific cancer/testis (CTA) antigens and neoantigens may benefit from large-scale tumor HLA peptidome (immunopeptidome) analysis, which aims to accurately identify antigens presented by tumor cells. While significant efforts have been invested in ...
ORGANISM(S): Homo sapiens (Human) 
2020-05-27 | PXD016060 | Pride
Patient derived xenograft Tumor antigen Peptidome Hla 
GenomicsDiscovery of tumor specific antigens in acute myeloid leukemia.
Discovery of tumor specific antigens in acute myeloid leukemia.
PRJNA615163 | ENA
TranscriptomicsCellular Transcriptional Responses to Merkel cell polyomavirus T antigens
Merkel cell polyomavirus (MCV) is clonally integrated in over 80% of Merkel cell carcinomas and mediates tumor development through the expression of viral oncoproteins large T (LT) and small T antigens (sT). Viral integration is associated with signature mutations in the T antigen locus that result ...
ORGANISM(S): Homo sapiens 
2015-09-21 | E-GEOD-68503 | biostudies-arrayexpress
GenomicsPan-cancer tumor-specific antigens and membrane targets from transposable elements
Pan-cancer tumor-specific antigens and membrane targets from transposable elements
PRJNA828030 | ENA
ProteomicsDiscovery of tumor-specific antigens in colorectal cancer
Colorectal cancer is the second leading cause of cancer death worldwide, and the incidence of this disease is expected to increase as global socioeconomic changes occur. Immune checkpoint inhibition therapy is effective in treating a minority of colorectal cancer tumors; however, microsatellite stab...
ORGANISM(S): Homo sapiens (Human) 
2022-04-13 | PXD028309 | Pride
Lc-msms Colorectal cancer Immunopeptidome Mhc class i 
GenomicsNoncoding regions are the main source of targetable tumor-specific antigens
Noncoding regions are the main source of targetable tumor-specific antigens
PRJNA525590 | ENA
MetabolomicsPharmacological Targeting of ALDH1a2 in Dendritic Cells Enhances Antigen Presentation, T Cell Activation and Anti-tumor immunity
Dendritic cell (DC) vaccines have been proposed as cancer immunotherapies due to their role as crucial antigen-presenting cells that regulate T cell functions. Despite considerable efforts to optimize ex vivo priming of DCs, DC vaccines have rarely been successful, suggesting the presence of unknown...
2025-11-03 | MTBLS10389 | MetaboLights
GenomicsNon-coding regions are the main source of tumor-specific antigens [human]
Non-coding regions are the main source of tumor-specific antigens [human]
PRJNA454710 | ENA
ProteomicsMEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma – namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors, and targeted immunotherapies – may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD029860 | Pride
Hla Mhc Immunopeptidomics Antigen presentation 
Sort   by:  
 Page size